CA3235810A1 - Dispositif et procede de dilatation d'une structure anatomique tubulaire - Google Patents
Dispositif et procede de dilatation d'une structure anatomique tubulaire Download PDFInfo
- Publication number
- CA3235810A1 CA3235810A1 CA3235810A CA3235810A CA3235810A1 CA 3235810 A1 CA3235810 A1 CA 3235810A1 CA 3235810 A CA3235810 A CA 3235810A CA 3235810 A CA3235810 A CA 3235810A CA 3235810 A1 CA3235810 A1 CA 3235810A1
- Authority
- CA
- Canada
- Prior art keywords
- optical fiber
- dilation
- artery
- tip
- conical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000010339 dilation Effects 0.000 title claims abstract description 98
- 238000000034 method Methods 0.000 title claims abstract description 78
- 210000003484 anatomy Anatomy 0.000 title claims abstract description 36
- 239000013307 optical fiber Substances 0.000 claims abstract description 125
- 210000001367 artery Anatomy 0.000 claims abstract description 67
- 238000013151 thrombectomy Methods 0.000 claims abstract description 44
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 36
- 230000000916 dilatatory effect Effects 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 72
- 229910003460 diamond Inorganic materials 0.000 claims description 41
- 239000010432 diamond Substances 0.000 claims description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000005350 fused silica glass Substances 0.000 claims description 22
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 20
- 230000003287 optical effect Effects 0.000 claims description 9
- 150000002826 nitrites Chemical class 0.000 claims description 7
- 238000004891 communication Methods 0.000 claims description 4
- 210000003123 bronchiole Anatomy 0.000 claims description 3
- 210000002460 smooth muscle Anatomy 0.000 claims description 3
- 210000005239 tubule Anatomy 0.000 claims description 3
- 210000000626 ureter Anatomy 0.000 claims description 3
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 abstract description 54
- 238000000605 extraction Methods 0.000 abstract description 16
- 230000002085 persistent effect Effects 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 7
- 238000004090 dissolution Methods 0.000 abstract description 4
- 241000124008 Mammalia Species 0.000 abstract description 3
- 230000001678 irradiating effect Effects 0.000 abstract description 2
- 230000006378 damage Effects 0.000 description 27
- 239000000835 fiber Substances 0.000 description 27
- 239000000377 silicon dioxide Substances 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 208000031481 Pathologic Constriction Diseases 0.000 description 13
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 239000004033 plastic Substances 0.000 description 12
- 229920003023 plastic Polymers 0.000 description 12
- 230000024883 vasodilation Effects 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 11
- 230000002792 vascular Effects 0.000 description 10
- 229910052688 Gadolinium Inorganic materials 0.000 description 9
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 9
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 9
- 229910001928 zirconium oxide Inorganic materials 0.000 description 9
- 239000002872 contrast media Substances 0.000 description 8
- 210000003038 endothelium Anatomy 0.000 description 8
- 210000001841 basilar artery Anatomy 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000036262 stenosis Effects 0.000 description 7
- 208000037804 stenosis Diseases 0.000 description 7
- 239000012780 transparent material Substances 0.000 description 7
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 230000003511 endothelial effect Effects 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 210000001147 pulmonary artery Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 4
- 206010047163 Vasospasm Diseases 0.000 description 4
- -1 argon ion Chemical class 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 206010002329 Aneurysm Diseases 0.000 description 3
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- 238000002399 angioplasty Methods 0.000 description 3
- 208000021328 arterial occlusion Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000008081 blood perfusion Effects 0.000 description 2
- 210000001601 blood-air barrier Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 210000001627 cerebral artery Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 210000003657 middle cerebral artery Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 208000002815 pulmonary hypertension Diseases 0.000 description 2
- 230000036593 pulmonary vascular resistance Effects 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 229960000103 thrombolytic agent Drugs 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 208000014882 Carotid artery disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 201000008450 Intracranial aneurysm Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 208000004717 Ruptured Aneurysm Diseases 0.000 description 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009118 appropriate response Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 208000021138 brain aneurysm Diseases 0.000 description 1
- 208000037876 carotid Atherosclerosis Diseases 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000005566 electron beam evaporation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000013152 interventional procedure Methods 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229910052743 krypton Inorganic materials 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000010417 nitric oxide pathway Effects 0.000 description 1
- 238000007034 nitrosation reaction Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920013744 specialty plastic Polymers 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- ICRHORQIUXBEPA-UHFFFAOYSA-N thionitrous acid Chemical compound SN=O ICRHORQIUXBEPA-UHFFFAOYSA-N 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
- G02B6/24—Coupling light guides
- G02B6/26—Optical coupling means
- G02B6/262—Optical details of coupling light into, or out of, or between fibre ends, e.g. special fibre end shapes or associated optical elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00345—Vascular system
- A61B2018/00404—Blood vessels other than those in or around the heart
- A61B2018/0041—Removal of thrombosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N2005/0602—Apparatus for use inside the body for treatment of blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
- A61N2005/0604—Lungs and/or airways
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
- A61N2005/061—Bladder and/or urethra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/063—Radiation therapy using light comprising light transmitting means, e.g. optical fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Laser Surgery Devices (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Abstract
L'invention concerne un procédé et un dispositif destinés à dilater une structure anatomique tubulaire. Le dispositif et le procédé peuvent être utiles pour extraire un caillot sanguin dans une artère d'un mammifère par irradiation concentrique d'une paroi interne de l'artère obstruée à l'aide d'un faisceau laser ultraviolet (UV) délivré par une fibre optique ayant une extrémité conique externe ou inversée. La dilatation résulte de la production photophysique et de la libération d'oxyde nitrique à partir des cellules qui recouvrent la paroi artérielle lorsque la lumière laser UV est projetée sous la forme d'un faisceau annulaire sur la paroi artérielle interne. Ce « système de dilatation permanente à contact minimal » prépare l'artère pour une extraction mécanique plus sûre par thrombectomie, du fait de la diminution du frottement et de la dissolution de la liaison chimique.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2021/056347 WO2023069118A1 (fr) | 2021-10-22 | 2021-10-22 | Dispositif et procédé de dilatation d'une structure anatomique tubulaire |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3235810A1 true CA3235810A1 (fr) | 2023-04-27 |
Family
ID=86058515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3235810A Pending CA3235810A1 (fr) | 2021-10-22 | 2021-10-22 | Dispositif et procede de dilatation d'une structure anatomique tubulaire |
Country Status (2)
| Country | Link |
|---|---|
| CA (1) | CA3235810A1 (fr) |
| WO (1) | WO2023069118A1 (fr) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5303324A (en) * | 1992-10-29 | 1994-04-12 | American Cyanamid Company | Method and apparatus for providing controlled light distribution from a cylindrical fiberoptic diffuser |
| US6539944B1 (en) * | 1999-06-11 | 2003-04-01 | Brant D. Watson | Dethrombosis facilitated by vasodilation |
| WO2003065880A2 (fr) * | 2002-02-05 | 2003-08-14 | Pharmacyclics, Inc. | Dispositif de transmission de lumiere faisant intervenir un systeme de diffusion conique et son procede de fabrication |
| CN111701144B (zh) * | 2015-07-28 | 2023-03-21 | 诺欧生物有限责任公司 | 用于对一氧化氮的光疗调节的系统和方法 |
-
2021
- 2021-10-22 WO PCT/US2021/056347 patent/WO2023069118A1/fr active Application Filing
- 2021-10-22 CA CA3235810A patent/CA3235810A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023069118A1 (fr) | 2023-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2569428C (fr) | Methodes et dispositifs pour le traitement de la plaque vulnerable | |
| Abela et al. | Laser angioplasty with angioscopic guidance in humans | |
| US5593403A (en) | Method for modifying a stent in an implanted site | |
| US4799479A (en) | Method and apparatus for angioplasty | |
| Dretler | An evaluation of ureteral laser lithotripsy: 225 consecutive patients | |
| US5019075A (en) | Method and apparatus for angioplasty | |
| Matsuoka et al. | Holmium: yttrium-aluminum-garnet laser for endoscopic lithotripsy | |
| US6962584B1 (en) | Electromagnetic photonic catheter for reducing restenosis | |
| Corcos et al. | The immediate effects of endovenous diode 808-nm laser in the greater saphenous vein: morphologic study and clinical implications | |
| JPH06501859A (ja) | 紫外線照射による再狭窄の抑制 | |
| JPS6173644A (ja) | 血管再生装置およびその使用方法 | |
| US6539944B1 (en) | Dethrombosis facilitated by vasodilation | |
| US20230270498A1 (en) | Device and method for dilation of a tubular anatomical structure | |
| JP2024020344A (ja) | 選択した血管又はその一部の修復、及び傷ついた体腔内壁の迅速な治癒のための機器及び方法 | |
| EP1458301A1 (fr) | Methode de traitement des occlusions vasculaires par inhibition de l'agregation plaquettaire | |
| Richard Spears | Percutaneous laser treatment of atherosclerosis: An overview of emerging techniques | |
| US11446089B1 (en) | Device and method for dilation of a tubular anatomical structure | |
| CA3235810A1 (fr) | Dispositif et procede de dilatation d'une structure anatomique tubulaire | |
| WO2023183896A2 (fr) | Dispositif et procédé de dilatation d'une structure anatomique tubulaire | |
| Takekawa et al. | Laser Angioplasty-Fundamental Studies and Initial Clinical Experience | |
| Geschwind et al. | Laser angioplasty of arterial stenoses | |
| Verdaasdonck et al. | Multifiber excimer laser catheter design strategies for various medical applications | |
| Gal et al. | Silver Halide Fibers For Surgical Applications Of CO [sub] 2 [/sub] Laser | |
| Geschwind et al. | Recanalization of human arteries using Nd-YAG laser carried by optical fibre | |
| Michaels et al. | The current status of laser angioplasty |